文献速递精神分裂症与精神病性障碍

22q11.2拷贝数变异携带者纹状体多巴胺能改变及其对精神病风险的意义:一项[18F]-DOPA PET研究

Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.
PubMed 文献 · Mol Psychiatry · 2021-05-12

该研究纳入21例22q11.2缺失、12例22q11.2重复携带者和26名健康对照,用[18F]-DOPA PET测量纹状体Kicer。缺失组纹状体Kicer显著高于对照组和重复组,且Kicer与精神病风险症状严重程度正相关,而在后来发生精神病的一名受试者中随时间升高。提示精神病遗传风险与多巴胺合成能力改变相关。

要点

  • 22q11.2缺失携带者纹状体多巴胺合成能力显著高于健康对照和重复携带者。
  • 纹状体Kicer与精神病风险症状严重程度正相关,与焦虑抑郁症状无关。
  • 一名后来发生精神病的受试者纹状体Kicer随时间升高。

核心结论

  • 精神病遗传风险与纹状体多巴胺合成能力改变相关,多巴胺合成可能是22q11.2缺失携带者精神病治疗或预防的潜在靶点。

主要发现

  • 拷贝数变异数目对纹状体Kicer值呈负向线性效应(B = -1.2 × 10-3,SE = 2 × 10-4,p < 0.001),对照组水平介于两变异组之间。
  • 22q11.2缺失组纹状体Kicer显著高于健康对照组(p < 0.001,Cohen's d = 1.44)和22q11.2重复组(p < 0.001,Cohen's d = 2)。
  • Kicer与精神病风险症状严重程度正相关(B = 730.5,SE = 310.2,p < 0.05)。
  • Kicer在后来发生精神病的一名受试者中随时间升高。
  • Kicer与焦虑或抑郁症状无关联。

临床怎么用

  • 在22q11.2缺失携带者中,纹状体多巴胺合成能力可能作为精神病风险的生物学指标。
  • 多巴胺合成通路可能成为22q11.2缺失携带者精神病预防或治疗的潜在干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dopaminergic dysregulation is one of the leading hypotheses for the pathoetiology underlying psychotic disorders such as schizophrenia. Molecular imaging studies have shown increased striatal dopamine synthesis capacity (DSC) in schizophrenia and people in the prodrome of psychosis. However, it is unclear if genetic risk for psychosis is associated with altered DSC. To investigate this, we recruited healthy controls and two antipsychotic naive groups of individuals with copy number variants, one with a genetic deletion at chromosome 22q11.2, and the other with a duplication at the same locus, who are at increased and decreased risk for psychosis, respectively. Fifty-nine individuals (21 with 22q11.2 deletion, 12 with the reciprocal duplication and 26 healthy controls) received clinical measures and [18F]-DOPA PET imaging to index striatal Kicer. There was an inverse linear effect of copy number variant number on striatal Kicer value (B = -1.2 × 10-3, SE = 2 × 10-4, p < 0.001), with controls showing levels intermediate between the two variant groups. Striatal Kicer was significantly higher in the 22q11.2 deletion group compared to the healthy control (p < 0.001, Cohen's d = 1.44) and 22q11.2 duplication (p < 0.001, Cohen's d = 2) groups. Moreover, Kicer was positively correlated with the severity of psychosis-risk symptoms (B = 730.5, SE = 310.2, p < 0.05) and increased over time in the subject who went on to develop psychosis, but was not associated with anxiety or depressive symptoms. Our findings suggest that genetic risk for psychosis is associated with dopaminergic dysfunction and identify dopamine synthesis as a potential target for treatment or prevention of psychosis in 22q11.2 deletion carriers.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Rogdaki M, Devroye C, Ciampoli M, et al. Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Mol Psychiatry. 2021. PMID: 33981004. doi:10.1038/s41380-021-01108-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。